From uncertainty on how to treat patients in the first few weeks to now using steroids such as dexamethasone, a lot has changed in Covid care over the last 5 months.
Gilead CEO Daniel O'Day wrote in an open letter that the drug's ability to reduce hospital stays by four days equates to savings of $12,000 per patient in the US
Gilead said it would offer this price to developed countries around the world in order to create a one-price model that would avoid country-by-country negotiations that could slow down access.
In a new set of protocols, the ministry backtracked from its earlier stance and recommended HCQ in the early course of the disease but not in severe cases.
The non-exclusive licensing agreement covers 127 countries, including India. Remdesivir is currently approved in the US for the emergency Covid treatment.
Gilead Sciences says it will ‘work closely with the health authorities in India to provide guidance on anticipated drug supply based on local incidence and severity of disease’.
The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.
While the commission didn’t mention provisions under which IndiGo's market domination would be examined, Competition Act 2002 prohibits abuse of dominant position by any enterprise.
It is argued that India-Israel ties are moving from buyer–seller dynamic to one focused on joint development & manufacturing partnership, a shift 'more durable' than traditional arms sales.
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
It is surprising that high priced drugs like remdesivir and favipiravir are accepted without any sufficiently successful clinically controlled double blind studies, but when Desi Ramdev baba takes the trials successfully, the system is not even ready to examine whether his results are authentic. So much for presence of powerful Pharma lobby.
It is surprising that high priced drugs like remdesivir and favipiravir are accepted without any sufficiently successful clinically controlled double blind studies, but when Desi Ramdev baba takes the trials successfully, the system is not even ready to examine whether his results are authentic. So much for presence of powerful Pharma lobby.